Metronomic Chemotherapy
Open Access
- 6 May 2021
- Vol. 13 (9), 2236
- https://doi.org/10.3390/cancers13092236
Abstract
Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi-target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle-income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.Keywords
This publication has 132 references indexed in Scilit:
- Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort ReportThe Breast Journal, 2012
- Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological ActivityClinical Breast Cancer, 2012
- Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancerCancer Chemotherapy and Pharmacology, 2012
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersAngiogenesis, 2012
- An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II studyCancer Chemotherapy and Pharmacology, 2011
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsBritish Journal of Cancer, 2008
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971